ChristopherWilliamMcQuinnMD

PubMed

• 4 citations
  Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell- and CXCR3-dependent manner.
  Michael Brandon Ware, Maggie Phillips, Christopher McQuinn, Mohammad Y Zaidi, Hannah M Knochelmann, Emily Greene, Brian Robinson, Cameron J Herting, Thomas A Mace, Zhe...> ;JCI Insight. 2023 Apr 24
• 13 citations
  A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186
  Cameron Herting, Matthew R. Farren, Yan Tong, Ziyue Liu, Bert H. O'Neil, Tanios Bekaii-Saab, Anne M. Noonan, Christopher McQuinn, Thomas A. Mace, Walid L. Shaib, Chris...> ;Cancer Immunology, Immunotherapy. 2021 Jun 23
• 12 citations
  Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable b...
  Robert Wesolowski, Andrew Stiff, Dionisia Quiroga, Christopher McQuinn, Zaibo Li, Hiroaki Nitta, Himanshu Savardekar, Brooke Benner, Bhuvaneswari Ramaswamy, Maryam B. ...> ;BMC Cancer. 2020 May 19
• 341 citations
  IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
  Thomas A. Mace, Reena Shakya, Jason R. Pitarresi, Benjamin Swanson, Christopher McQuinn, Shannon Loftus, Emily Nordquist, Zobeida Cruz-Monserrate, Lianbo Yu, Gregory S...> ;Gut. 2018 Feb 1
• Join now to see all